西洛他唑在股腘动脉病变血管内治疗后的持续有效性:STOP-IC 研究中期随访
STOP-IC 研究将 200 例股腘动脉病变患者随机分配至阿司匹林联合或不联合西洛他唑组,随访中位 38.1 个月。西洛他唑组 3 年一期通畅率显著高于对照组(69% vs 54%,p=0.026),CD-TLR 免除率亦更优(78% vs 63%,p=0.014),总生存无显著差异。
要点
- 西洛他唑组 3 年一期通畅率 69%,对照组 54%,差异显著(p=0.026)。
- 西洛他唑组 3 年 CD-TLR 免除率 78%,对照组 63%,差异显著(p=0.014)。
- 两组总生存估计无显著差异(p=0.95)。
核心结论
- 结果表明,股腘动脉病变患者血管内治疗后西洛他唑治疗的安全性和有效性持续存在。
研究设计与样本
- STOP-IC 研究(ClinicalTrials.gov 标识 NCT00912756;University Hospital Medical Information Network 标识 UMIN000002091)于 2009 年 3 月至 2011 年 4 月在日本 13 家心血管中心纳入 200 例股腘动脉病变患者(平均年龄 73 岁;131 例男性)。
- 参与者按 1:1 随机接受口服阿司匹林联合或不联合西洛他唑;西洛他唑组 7 例、无西洛他唑组 2 例未接受血管内治疗而退出,最终西洛他唑组 93 例、无西洛他唑组 98 例纳入随访分析。
- 主要结局为一期通畅率;次要结局为临床驱动的靶病变血运重建(CD-TLR)免除率和总生存;按意向性治疗原则用 Kaplan-Meier 法分析,以 log-rank 检验比较估计值。
主要发现
- 中位随访 38.1 个月(四分位距 25.1,47.7)。
- 西洛他唑组 93 例中 7 例死亡,26 例在血管内操作 1 年后退出给药;停用西洛他唑不是再狭窄的显著因素。
- 3 年一期通畅率西洛他唑组 69% vs 无西洛他唑组 54%,差异显著(p=0.026)。
- 3 年 CD-TLR 免除率西洛他唑组 78% vs 无西洛他唑组 63%,差异显著(p=0.014)。
- 总生存估计两组无显著差异(p=0.95)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the midterm safety and effectiveness of cilostazol treatment in claudicant patients undergoing endovascular therapy. METHODS: The Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) study ( ClinicalTrials.gov identifier NCT00912756; University Hospital Medical Information Network identifier UMIN000002091) enrolled 200 patients (mean age 73 years; 131 men) treated for femoropopliteal disease from March 2009 to April 2011 at 13 cardiovascular centers in Japan. The participants were randomized 1:1 to receive oral aspirin with or without cilostazol. Of the 100 patients assigned to the 2 treatment groups, 7 patients in the cilostazol group and 2 patients in the no-cilostazol group were withdrawn from the study without undergoing endovascular treatment, leaving 93 patients in the cilostazol group and 98 patients in the no-cilostazol group for follow-up analysis. The primary outcome measure was primary patency; secondary outcome measures were freedom from clinically-driven target lesion revascularization (CD-TLR) and overall survival. Outcomes were analyzed on an intention-to-treat basis using the Kaplan-Meier method; estimates were compared with the log-rank test. RESULTS: The median follow-up was 38.1 months (interquartile range 25.1, 47.7). Among the 93 subjects in the cilostazol group, 7 died and 26 withdrew from administration 1 year after the endovascular procedure. Discontinuation of cilostazol was not a significant factor for restenosis. Primary patency was significantly higher in the cilostazol group than in the no-cilostazol group (69% vs 54%, p=0.026) at 3 years. The cilostazol group also had better 3-year freedom from CD-TLR (78% vs 63%, p=0.014), although overall survival estimates did not differ significantly (p=0.95). CONCLUSION: These results suggest that the safety and effectiveness of cilostazol treatment were sustained in patients with femoropopliteal disease undergoing endovascular treatment.
引用
- Soga Y, Hamasaki T, Edahiro R, et al. Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study. J Endovasc Ther. 2018. PMID: 29706129. doi:10.1177/1526602818771358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。